Cargando…

Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial

BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarasate, Mikel, González, Nuria, Córdoba-Izquierdo, Ana, Prats, Enric, Gonzalez-Moro, Jose Miguel Rodriguez, Martí, Sergi, Lujan, Manel, Calle, Myriam, Antón, Antonio, Povedano, Mónica, Farrero, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357175/
https://www.ncbi.nlm.nih.gov/pubmed/37212068
http://dx.doi.org/10.3233/JND-221658
_version_ 1785075438617362432
author Sarasate, Mikel
González, Nuria
Córdoba-Izquierdo, Ana
Prats, Enric
Gonzalez-Moro, Jose Miguel Rodriguez
Martí, Sergi
Lujan, Manel
Calle, Myriam
Antón, Antonio
Povedano, Mónica
Farrero, Eva
author_facet Sarasate, Mikel
González, Nuria
Córdoba-Izquierdo, Ana
Prats, Enric
Gonzalez-Moro, Jose Miguel Rodriguez
Martí, Sergi
Lujan, Manel
Calle, Myriam
Antón, Antonio
Povedano, Mónica
Farrero, Eva
author_sort Sarasate, Mikel
collection PubMed
description BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of this study is to evaluate whether early use of NIV improves the prognosis of ALS patients compared with standard initiation. METHODS: This is a randomized, parallel, multicenter, open-label, controlled clinical trial, with recruitment at the ALS outpatient multidisciplinary units of six Spanish hospitals. Patients were included when their FVC reached the 75% threshold and were randomized by computer, stratifying by center in an allocation ratio of 1:1 to Early NIV (FVC below 75%) or Standard NIV (FVC below 50%) initiation. The primary outcome was time to death or tracheostomy. Trial registration number ClinicalTrials.gov: NCT01641965. RESULTS: Between May 2012 and June 2014, 42 patients were randomized to two groups, 20 to Early NIV and 22 to Standard NIV initiation. We found differences in survival in favor of the intervention group: an incidence of mortality (2.68 [1.87–5.50] vs. 3.33 [1.34–4.80] person-months) and a median survival (25.2 vs. 19.4 months), although without reaching statistical significance (p = 0.267). CONCLUSIONS: This trial did not reach the primary endpoint of survival; nevertheless, it is the first Randomized Controlled Trial (RCT) to demonstrate the benefits of early NIV in slowing the decline of respiratory muscle strength and reducing adverse events. Although not all the results reached statistical significance, all the analyzed data favor early NIV. In addition, this study demonstrates good tolerance and compliance with early NIV without quality of sleep impairment. These data reinforce the early respiratory evaluation of ALS patients and NIV initiation with an FVC of around 75%.
format Online
Article
Text
id pubmed-10357175
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-103571752023-07-21 Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial Sarasate, Mikel González, Nuria Córdoba-Izquierdo, Ana Prats, Enric Gonzalez-Moro, Jose Miguel Rodriguez Martí, Sergi Lujan, Manel Calle, Myriam Antón, Antonio Povedano, Mónica Farrero, Eva J Neuromuscul Dis Research Report BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of this study is to evaluate whether early use of NIV improves the prognosis of ALS patients compared with standard initiation. METHODS: This is a randomized, parallel, multicenter, open-label, controlled clinical trial, with recruitment at the ALS outpatient multidisciplinary units of six Spanish hospitals. Patients were included when their FVC reached the 75% threshold and were randomized by computer, stratifying by center in an allocation ratio of 1:1 to Early NIV (FVC below 75%) or Standard NIV (FVC below 50%) initiation. The primary outcome was time to death or tracheostomy. Trial registration number ClinicalTrials.gov: NCT01641965. RESULTS: Between May 2012 and June 2014, 42 patients were randomized to two groups, 20 to Early NIV and 22 to Standard NIV initiation. We found differences in survival in favor of the intervention group: an incidence of mortality (2.68 [1.87–5.50] vs. 3.33 [1.34–4.80] person-months) and a median survival (25.2 vs. 19.4 months), although without reaching statistical significance (p = 0.267). CONCLUSIONS: This trial did not reach the primary endpoint of survival; nevertheless, it is the first Randomized Controlled Trial (RCT) to demonstrate the benefits of early NIV in slowing the decline of respiratory muscle strength and reducing adverse events. Although not all the results reached statistical significance, all the analyzed data favor early NIV. In addition, this study demonstrates good tolerance and compliance with early NIV without quality of sleep impairment. These data reinforce the early respiratory evaluation of ALS patients and NIV initiation with an FVC of around 75%. IOS Press 2023-07-04 /pmc/articles/PMC10357175/ /pubmed/37212068 http://dx.doi.org/10.3233/JND-221658 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Sarasate, Mikel
González, Nuria
Córdoba-Izquierdo, Ana
Prats, Enric
Gonzalez-Moro, Jose Miguel Rodriguez
Martí, Sergi
Lujan, Manel
Calle, Myriam
Antón, Antonio
Povedano, Mónica
Farrero, Eva
Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title_full Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title_fullStr Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title_full_unstemmed Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title_short Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
title_sort impact of early non-invasive ventilation in amyotrophic lateral sclerosis: a multicenter randomized controlled trial
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357175/
https://www.ncbi.nlm.nih.gov/pubmed/37212068
http://dx.doi.org/10.3233/JND-221658
work_keys_str_mv AT sarasatemikel impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT gonzaleznuria impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT cordobaizquierdoana impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT pratsenric impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT gonzalezmorojosemiguelrodriguez impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT martisergi impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT lujanmanel impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT callemyriam impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT antonantonio impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT povedanomonica impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial
AT farreroeva impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial